logo-loader
RNS
viewAstraZeneca

AstraZeneca divests rights to Seroquel and

/**/ em{letter-spacing:.5pt;border:none windowtext 1.0pt;padding:0cm;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .ap{size:21.0cm 842.0pt;margin:3.0cm 72.0pt 0cm 72.0pt;}div.ap{}p.cf{margin:0cm;margin-bottom:.0001pt;line-height:120%;text-autospace:none;font-size:11.0pt;font-family:"Arial","sans-serif";color:black;font-weight:bold;line-height:115%}span.cd{font-weight:normal}span.cb{font-size:12.0pt; line-height:115%}p.cg{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: 115%; text-align: center}span.ca{font-size:12.0pt;line-height:115%}p.ch{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: 115%; text-align: justify}span.by{color:black}p.ci{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";line-height: 115%; text-align: center} .bv{font-div: italic}span.bw{line-height:115%;color:black}span.bu{line-height:115%}p.cj{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: 115%}p.ck{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-align:justify;line-height:115%}span.bq{line-height:115%;color:black;letter-spacing:.25pt}span.bp{color: blue; line-height: 115%; text-decoration: underline}span.bo{line-height:115%;color:blue}table.cl{width:444.2pt;margin-left:-5.4pt;border-collapse:collapse}tr.bh{height:21.15pt} td.bl{width:35.1%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt}p.cm{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: 115%; page-break-after: avoid; text-align: justify; text-indent: -5.5pt}span.bn{font-size:10.0pt;line-height: 115%}td.bj{width:43.08%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt}span.bk{font-size:10.0pt;line-height:115%}td.bi{width:21.82%;padding:0cm 5.4pt 0cm 5.4pt;height:21.15pt}tr.ba{height:19.85pt}td.bf{width:35.1%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}p.cn{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-indent:-5.5pt;line-height:115%}td.bd{width:43.08%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt} p.co{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";line-height:115%}span.be{font-size:10.0pt; line-height:115%}td.bb{width:21.82%;padding:0cm 5.4pt 0cm 5.4pt; height:19.85pt}p.cp{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";line-height: 115%; text-align: right}td.az{width:35.1%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt}td.ay{width:43.08%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt}td.ax{width:21.82%;padding:0cm 5.4pt 0cm 5.4pt;height:19.85pt}span.aw{font-size:10.0pt;line-height:115%;color:black}p.cq{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: 115%; page-break-after: avoid; text-indent: -5.5pt}p.cr{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";text-indent:-5.5pt;line-height:115%;page-break-after: avoid} p.cs{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Arial","sans-serif";line-height:115%;text-autospace:none;vertical-align: middle}p.ct{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height:115%}span.ar{font-size:10.0pt; line-height:115%;font-family:"Arial","sans-serif";color:black}span.aq{font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"; color:black}p.cu{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%} /**/
RNS Number : 5420R
AstraZeneca PLC
30 October 2019
 

30 October 2019 07:00 GMT

 

AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia

 

Sale to Cheplapharm supports AstraZeneca's focus on main therapy areas

 

AstraZeneca has agreed the sale and licence of the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm). Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in Europe and Russia.

 

Ruud Dobber, Executive Vice President, Biopharmaceuticals, said: "Seroquel is an important established medicine and this agreement with Cheplapharm will help ensure continued patient access. It forms part of our strategy of reducing the portfolio of mature medicines to enable reinvestment in our main therapy areas."

 

AstraZeneca will continue to manufacture and supply Seroquel and Seroquel XR to Cheplapharm during a transition period.

 

Pursuant to Listing Rule 10.4.1R (notification of class 2 transactions), the gross book value of assets subject to the divestment as at 31 December 2018 was nil. In the year to 31 December 2018, the aggregate pre-tax profits attributable to Seroquel and Seroquel XR in the relevant territories were $86m. The consideration will be paid in cash and the proceeds used for general corporate purposes.

 

Financial considerations

Cheplapharm will make an upfront payment of $178m to AstraZeneca and may also make future sales-contingent payments of up to $61m. Income arising from the upfront and future payments will be reported in AstraZeneca's financial statements within Other Operating Income & Expense. In 2018, Seroquel generated annual product sales of $47m in the markets covered by this agreement, while Seroquel XR generated $61m. The agreement does not impact the Company's financial guidance for 2019. The transaction is expected to complete in the fourth quarter of 2019, subject to customary closing conditions and regulatory clearances.

 

About Seroquel

Seroquel and Seroquel XR are atypical anti-psychotic medicines with antidepressant properties. The main indications for Seroquel are the treatment of schizophrenia and bipolar disorder. Seroquel XR is also approved in some markets for major depressive disorder and generalised anxiety disorder.

 

AstraZeneca has previously disposed of the rights to Seroquel and Seroquel XR in the UK, Japan and other major international markets.

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Media Relations



Gonzalo Viña


+44 203 749 5916

Rob Skelding

Oncology

+44 203 749 5821

Rebecca Einhorn

Oncology

+1 301 518 4122

Matt Kent

BioPharmaceuticals

+44 203 749 5906

Jennifer Hursit

Other

+44 203 749 5762

Christina Malmberg Hägerstrand

Sweden

+46 8 552 53 106

Michele Meixell

US

+1 302 885 2677




Investor Relations



Thomas Kudsk Larsen


+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

BioPharmaceuticals (CV, Metabolism)

+44 203 749 5711

Nick Stone

BioPharmaceuticals (Renal), ESG

+44 203 749 5716

Josie Afolabi

BioPharmaceuticals (Respiratory),

other medicines

+44 203 749 5631

Craig Marks

Finance, fixed income

+44 7881 615 764

Jennifer Kretzmann

Corporate access, retail investors

+44 203 749 5824

US toll-free


+1 866 381 72 77

 

Adrian Kemp
Company Secretary

AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCKMMZGLLNGLZM

Quick facts: AstraZeneca

Price: 7306

Market: LSE
Market Cap: £95.85 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE